BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38696737)

  • 21. The spectrum of MOG autoantibody-associated demyelinating diseases.
    Reindl M; Di Pauli F; Rostásy K; Berger T
    Nat Rev Neurol; 2013 Aug; 9(8):455-61. PubMed ID: 23797245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
    Ringelstein M; Ayzenberg I; Lindenblatt G; Fischer K; Gahlen A; Novi G; Hayward-Könnecke H; Schippling S; Rommer PS; Kornek B; Zrzavy T; Biotti D; Ciron J; Audoin B; Berthele A; Giglhuber K; Zephir H; Kümpfel T; Berger R; Röther J; Häußler V; Stellmann JP; Whittam D; Jacob A; Kraemer M; Gueguen A; Deschamps R; Bayas A; Hümmert MW; Trebst C; Haarmann A; Jarius S; Wildemann B; Grothe M; Siebert N; Ruprecht K; Paul F; Collongues N; Marignier R; Levy M; Karenfort M; Deppe M; Albrecht P; Hellwig K; Gold R; Hartung HP; Meuth SG; Kleiter I; Aktas O;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34785575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis, Clinical Features, and Treatment of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Autoantibody-Associated Disorders Focusing on Optic Neuritis with Consideration of Autoantibody-Binding Sites: A Review.
    Tanaka K; Kezuka T; Ishikawa H; Tanaka M; Sakimura K; Abe M; Kawamura M
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies.
    Zhou L; ZhangBao J; Li H; Li X; Huang Y; Wang M; Zhao C; Lu J; Lu C; Li Y; Quan C
    Mult Scler Relat Disord; 2017 Nov; 18():90-92. PubMed ID: 29141829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.
    Konuskan B; Yildirim M; Gocmen R; Okur TD; Polat I; Kilic H; Saltik S; Ozturk Z; Gucuyener K; Altunbasak S; Celik T; Kose G; Yilmaz A; Komur M; Kayilioglu H; Anlar B
    Mult Scler Relat Disord; 2018 Nov; 26():1-7. PubMed ID: 30212767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review.
    Elsbernd PM; Hoffman WR; Carter JL; Wingerchuk DM
    Mult Scler Relat Disord; 2021 Feb; 48():102696. PubMed ID: 33360264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies.
    Lee HJ; Kim B; Waters P; Woodhall M; Irani S; Ahn S; Kim SJ; Kim SM
    J Neuroinflammation; 2018 Oct; 15(1):302. PubMed ID: 30382857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases.
    Baumann M; Hennes EM; Schanda K; Karenfort M; Kornek B; Seidl R; Diepold K; Lauffer H; Marquardt I; Strautmanis J; Syrbe S; Vieker S; Höftberger R; Reindl M; Rostásy K
    Mult Scler; 2016 Dec; 22(14):1821-1829. PubMed ID: 26869530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
    Ramanathan S; Mohammad S; Tantsis E; Nguyen TK; Merheb V; Fung VSC; White OB; Broadley S; Lechner-Scott J; Vucic S; Henderson APD; Barnett MH; Reddel SW; Brilot F; Dale RC;
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):127-137. PubMed ID: 29142145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Potential Pathogenicity of Myelin Oligodendrocyte Glycoprotein Antibodies in the Optic Pathway.
    Lerch M; Bauer A; Reindl M
    J Neuroophthalmol; 2023 Mar; 43(1):5-16. PubMed ID: 36729854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes.
    Waters P; Fadda G; Woodhall M; O'Mahony J; Brown RA; Castro DA; Longoni G; Irani SR; Sun B; Yeh EA; Marrie RA; Arnold DL; Banwell B; Bar-Or A;
    JAMA Neurol; 2020 Jan; 77(1):82-93. PubMed ID: 31545352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of MOG encephalomyelitis with T- cell lymphoma.
    Kwon YN; Koh J; Jeon YK; Sung JJ; Park SH; Kim SM
    Mult Scler Relat Disord; 2020 Jun; 41():102038. PubMed ID: 32155461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Marignier R; Hacohen Y; Cobo-Calvo A; Pröbstel AK; Aktas O; Alexopoulos H; Amato MP; Asgari N; Banwell B; Bennett J; Brilot F; Capobianco M; Chitnis T; Ciccarelli O; Deiva K; De Sèze J; Fujihara K; Jacob A; Kim HJ; Kleiter I; Lassmann H; Leite MI; Linington C; Meinl E; Palace J; Paul F; Petzold A; Pittock S; Reindl M; Sato DK; Selmaj K; Siva A; Stankoff B; Tintore M; Traboulsee A; Waters P; Waubant E; Weinshenker B; Derfuss T; Vukusic S; Hemmer B
    Lancet Neurol; 2021 Sep; 20(9):762-772. PubMed ID: 34418402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
    Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
    JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review.
    Gombolay GY; Gadde JA
    J Neuroimmunol; 2021 Sep; 358():577653. PubMed ID: 34229204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
    Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Right optic perineuritis and myelitis 6 years following left optic perineuritis in anti-myelin oligodendrocyte glycoprotein-associated disorder: a case report].
    Maruta K; Nobuhara Y; Ijiri Y; Kojima F; Takashima H
    Rinsho Shinkeigaku; 2022 Apr; 62(4):286-292. PubMed ID: 35354728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.